The Functionality of Apigenin as a Novel Cardioprotective Nutraceutical with Emphasize on Regulating Cardiac Micro RNAs:

Shahabi Raberi V, Venus Shahabi Raberi, Mahboubeh Esmati, Esmati M, Haleh Bodagh, Bodagh H, Reza Ghasemi, Ghasemi R, Mehrdad Ghazal, Ghazal M, Matinpour A, Azita Matinpour, Mohsen Abbasnezhad, Abbasnezhad M
Galen medical journal · 2022 · vol. 11 , pp. e2535 · doi:10.31661/gmj.v11i.2535 · PMID:37200687 · PMC10188251
Review OA: closed CC-BY-4.0
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-24 ⓘ

This review evaluates apigenin as a cardioprotective nutraceutical that regulates cardiac microRNAs to prevent cardiovascular diseases through mechanisms like reducing apoptosis and fibrosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-24 · read from full text ⓘ

This review article evaluates the cardioprotective properties of apigenin, a flavonoid nutraceutical, by analyzing its ability to regulate cardiac microRNAs such as miR-103, miR-122-5p, and miR-155. The authors synthesize evidence demonstrating that apigenin mitigates cardiovascular disease mechanisms through cholesterol efflux promotion, reduction of cardiocyte apoptosis, attenuation of myocyte fibrosis, and maintenance of oxidative balance via reactive oxygen species modulation. While the paper highlights these potential therapeutic benefits against various cardiovascular disorders, it functions primarily as a mechanistic overview rather than a clinical trial report. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Cardiovascular diseases (CVDs) are considered the most common disorder and the leading cause of mortality globally. The etiology of CVDs depends on a variety of genetic and acquired parameters. Nowadays, a dramatic surge appeared in published reports to find the association between microRNAs (miRNAs) and CVDs in order to understand the cause of the disease, rapid diagnosis with the introduction of valid biomarkers, and target as a therapeutic approach. Apigenin is a novel nutraceutical flavonoid that cardioprotective properties are suggested. The current review aimed to evaluate the beneficial features of this phytochemical against CVDs with an emphasis on its ability to regulate the miRNAs. The findings demonstrated that Apigenin could regulate cardiac miRNAs, including miR-103, miR-122-5p, miR-15b, miR-155, and miR-33. Consequently, preventing CVDs is possible through different effects such as the promotion of cholesterol efflux, prevention of hyperlipidemia, alteration in ATP Binding Cassette Subfamily A Member 1 (ABCA1) levels, reducing of cardiocytes apoptosis, and retarding myocytes fibrosis. Also, it can regulate signaling pathways, protect against endothelial dysfunction, maintain oxidative balance, and decrease inflammatory factors and reactive oxygen species. Hence, apigenin regulatory characteristics affecting miRNAs expression could introduce this flavonoid as a novel cardioprotective phytochemical against different CVDs.
Full text 2,104 characters · extracted from oa-doi-fallback · click to expand
The Functionality of Apigenin as a Novel Cardioprotective Nutraceutical with Emphasize on Regulating Cardiac Micro RNAs DOI: https://doi.org/10.31661/gmj.v11i.2535Keywords: Apigenin, Reactive Oxygen Species, Antioxidants, MicroRNAs, Cardiovascular DiseasesAbstract Cardiovascular diseases (CVDs) are considered the most common disorder and the leading cause of mortality globally. The etiology of CVDs depends on a variety of genetic and acquired parameters. Nowadays, a dramatic surge appeared in published reports to find the association between microRNAs (miRNAs) and CVDs in order to understand the cause of the disease, rapid diagnosis with the introduction of valid biomarkers, and target as a therapeutic approach. Apigenin is a novel nutraceutical flavonoid that cardioprotective properties are suggested. The current review aimed to evaluate the beneficial features of this phytochemical against CVDs with an emphasis on its ability to regulate the miRNAs. The findings demonstrated that Apigenin could regulate cardiac miRNAs, including miR-103, miR-122-5p, miR-15b, miR-155, and miR-33. Consequently, preventing CVDs is possible through different effects such as the promotion of cholesterol efflux, prevention of hyperlipidemia, alteration in ATP Binding Cassette Subfamily A Member 1 (ABCA1) levels, reducing of cardiocytes apoptosis, and retarding myocytes fibrosis. Also, it can regulate signaling pathways, protect against endothelial dysfunction, maintain oxidative balance, and decrease inflammatory factors and reactive oxygen species. Hence, apigenin regulatory characteristics affecting miRNAs expression could introduce this flavonoid as a novel cardioprotective phytochemical against different CVDs.Published 2022-12-17 How to Cite Abbasnezhad, M. ., Shahabi Raberi , V. ., Esmati , M., Bodagh, H. ., Ghasemi , R. ., Ghazal , M. ., & Matinpour , A. . (2022). The Functionality of Apigenin as a Novel Cardioprotective Nutraceutical with Emphasize on Regulating Cardiac Micro RNAs. Galen Medical Journal, 11, e2535. https://doi.org/10.31661/gmj.v11i.2535 Issue Section Review Article

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
pubmed
last seen: 2026-10-08T21:39:41.577707+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC